Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
QUINDOLINE
ID: ALA224248
Max Phase: Preclinical
Molecular Formula: C15H10N2
Molecular Weight: 218.26
Molecule Type: Small molecule
Associated Items:
ID: ALA224248
Max Phase: Preclinical
Molecular Formula: C15H10N2
Molecular Weight: 218.26
Molecule Type: Small molecule
Associated Items:
Synonyms (2): 10H-Indolo[3,2-B]Quinoline | Quindoline
Synonyms from Alternative Forms(2):
Canonical SMILES: c1ccc2nc3c(cc2c1)[nH]c1ccccc13
Standard InChI: InChI=1S/C15H10N2/c1-3-7-12-10(5-1)9-14-15(17-12)11-6-2-4-8-13(11)16-14/h1-9,16H
Standard InChI Key: QOAKRWLMTKEDDL-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: Yes | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 218.26 | Molecular Weight (Monoisotopic): 218.0844 | AlogP: 3.87 | #Rotatable Bonds: 0 |
Polar Surface Area: 28.68 | Molecular Species: NEUTRAL | HBA: 1 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 2 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.91 | CX Basic pKa: 4.50 | CX LogP: 3.63 | CX LogD: 3.63 |
Aromatic Rings: 4 | Heavy Atoms: 17 | QED Weighted: 0.48 | Np Likeness Score: -0.24 |
1. Caprio V, Guyen B, Opoku-Boahen Y, Mann J, Gowan SM, Kelland LM, Read MA, Neidle S.. (2000) A novel inhibitor of human telomerase derived from 10H-indolo[3,2-b]quinoline., 10 (18): [PMID:10999471] [10.1016/s0960-894x(00)00378-4] |
2. Wright CW, Addae-Kyereme J, Breen AG, Brown JE, Cox MF, Croft SL, Gökçek Y, Kendrick H, Phillips RM, Pollet PL.. (2001) Synthesis and evaluation of cryptolepine analogues for their potential as new antimalarial agents., 44 (19): [PMID:11543688] [10.1021/jm010929+] |
3. Arzel E, Rocca P, Grellier P, Labaeïd M, Frappier F, Guéritte F, Gaspard C, Marsais F, Godard A, Quéguiner G.. (2001) New synthesis of benzo-delta-carbolines, cryptolepines, and their salts: in vitro cytotoxic, antiplasmodial, and antitrypanosomal activities of delta-carbolines, benzo-delta-carbolines, and cryptolepines., 44 (6): [PMID:11300877] [10.1021/jm0010419] |
4. Zhou JL, Lu YJ, Ou TM, Zhou JM, Huang ZS, Zhu XF, Du CJ, Bu XZ, Ma L, Gu LQ, Li YM, Chan AS.. (2005) Synthesis and evaluation of quindoline derivatives as G-quadruplex inducing and stabilizing ligands and potential inhibitors of telomerase., 48 (23): [PMID:16279791] [10.1021/jm050041b] |
5. Cimanga K, De Bruyne T, Pieters L, Vlietinck AJ, Turger CA.. (1997) In vitro and in vivo antiplasmodial activity of cryptolepine and related alkaloids from Cryptolepis sanguinolenta., 60 (7): [PMID:9249972] [10.1021/np9605246] |
6. Yang SW, Abdel-Kader M, Malone S, Werkhoven MC, Wisse JH, Bursuker I, Neddermann K, Fairchild C, Raventos-Suarez C, Menendez AT, Lane K, Kingston DG.. (1999) Synthesis and biological evaluation of analogues of cryptolepine, an alkaloid isolated from the Suriname rainforest., 62 (7): [PMID:10425120] [10.1021/np990035g] |
7. Nuthakki VK, Mudududdla R, Bharate SB.. (2022) Role of basic aminoalkyl chains in the lead optimization of Indoloquinoline alkaloids., 227 [PMID:34710743] [10.1016/j.ejmech.2021.113938] |
Source(1):